Multiparametric MRI (mpMRI) is currently the test of choice for imaging sites of prostate cancer located within the pelvis. However, molecular imaging with PET radiotracers that bind to prostate-specific membrane antigen is increasingly being used for this purpose and may compliment mpMRI findings. We present a case of a 59-year-old man with elevated postprostatectomy serum prostate-specific antigen level who was found on both mpMRI and prostate-specific membrane antigen–targeted PET to harbor residual prostate cancer in the corpus spongiosum along the proximal urethra.
|Original language||English (US)|
|Journal||Clinical nuclear medicine|
|State||Published - Oct 1 2017|
- prostate MRI
- prostate cancer
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging